631 related articles for article (PubMed ID: 27064449)
1. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.
Luo J; Yang Z; Ma Y; Yue Z; Lin H; Qu G; Huang J; Dai W; Li C; Zheng C; Xu L; Chen H; Wang J; Li D; Siwko S; Penninger JM; Ning G; Xiao J; Liu M
Nat Med; 2016 May; 22(5):539-46. PubMed ID: 27064449
[TBL] [Abstract][Full Text] [Related]
2. An LGR4 agonist activates the GSK‑3β pathway to inhibit RANK‑RANKL signaling during osteoclastogenesis in bone marrow‑derived macrophages.
Jang Y; Lee H; Cho Y; Choi E; Jo S; Sohn HM; Kim BC; Ko YJ; Lim W
Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 38063193
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
5. RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis.
O'Brien W; Fissel BM; Maeda Y; Yan J; Ge X; Gravallese EM; Aliprantis AO; Charles JF
Arthritis Rheumatol; 2016 Dec; 68(12):2889-2900. PubMed ID: 27563728
[TBL] [Abstract][Full Text] [Related]
6. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.
Jang Y; Sohn HM; Ko YJ; Hyun H; Lim W
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406741
[TBL] [Abstract][Full Text] [Related]
8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
9. Low levels of cadmium exposure affect bone by inhibiting Lgr4 expression in osteoblasts and osteoclasts.
Wang M; Liu J; Zhu G; Chen X
J Trace Elem Med Biol; 2022 Sep; 73():127025. PubMed ID: 35772369
[TBL] [Abstract][Full Text] [Related]
10. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
11. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.
Ko YJ; Sohn HM; Jang Y; Park M; Kim B; Kim B; Park JI; Hyun H; Jeong B; Hong C; Lim W
Clin Transl Med; 2021 Mar; 11(3):e368. PubMed ID: 33784004
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
13. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
14. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
15. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
16. Selenoprotein W ensures physiological bone remodeling by preventing hyperactivity of osteoclasts.
Kim H; Lee K; Kim JM; Kim MY; Kim JR; Lee HW; Chung YW; Shin HI; Kim T; Park ES; Rho J; Lee SH; Kim N; Lee SY; Choi Y; Jeong D
Nat Commun; 2021 Apr; 12(1):2258. PubMed ID: 33859201
[TBL] [Abstract][Full Text] [Related]
17. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
Hsiao HB; Wu JB; Lin WC
BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
[TBL] [Abstract][Full Text] [Related]
19. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz A; Grynpas MD; Mitchell J
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
[TBL] [Abstract][Full Text] [Related]
20. Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts.
Kim JH; Youn BU; Kim K; Moon JB; Lee J; Nam KI; Park YW; O'Leary DD; Kim KK; Kim N
Cell Death Differ; 2014 Oct; 21(10):1613-21. PubMed ID: 24902903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
